中文名:二對(duì)甲苯磺酸拉帕替尼(GW-572016)
英文名:Lapatinib (GW-572016) Ditosylate
英文別名:N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,di4-methylbenzenesulfonate
純度:10mM in DMSO
貨號(hào):L408619
包裝:1ml
Cas號(hào):388082-77-7
存儲(chǔ)溫度:-80℃儲(chǔ)存
產(chǎn)品介紹:
Information
Lapatinib (GW-572016) Ditosylate is a potentEGFRandErbB2inhibitor withIC50of 10.8 and 9.2 nM in cell-free assays, respectively.
In?vitro
Lapatinib Ditosylate weakly inhibits the activity of ErbB4 with IC50 of 367 nM, and displays >300-fold selectivity for EGFR and ErbB2 over other kinases such as c-Src, c-Raf, MEK, ERK, c-Fms, CDK1, CDK2, p38, Tie-2, and VEGFR2. Lapatinib Ditosylate significantly inhibits receptor autophosphorylation of EGFR and ErbB2 in a dose-dependent manner with IC50 of 170 nM and 80 nM, respectively in HN5 cells; as well as 210 nM and 60 nM, respectively in BT474 cells. Unlike OSI-774 and Iressa (ZD1839) which preferentially inhibit the growth of the EGFR-overexpressing cells, Lapatinib Ditosylate inhibits the growth of both EGFR- and ErbB2-overexpressing cells. Lapatinib Ditosylate displays higher inhibitory activity against EGFR- or ErbB2-overexpressing cells with IC50 of 0.09-0.21 μM, compared with cells expressing low levels of EGFR or ErbB2 with IC50 of 3-12 μM, and exhibits ~100-fold selectivity over the normal fibroblast cells. Lapatinib Ditosylate potently inhibits the outgrowth of EGFR-overexpressing HN5 and A-431 cells, as well as ErbB2-overexpressing BT474 and N87 cells, and significantly induces G1 arrest of HN5 cells and apoptosis of BT474 cells, which are associated with inhibition of AKT phosphorylation.
In?vivo
Oral administration of Lapatinib Ditosylate (~100 mg/kg) twice daily significantly inhibits the growth of BT474 and HN5 xenografts in a dose-dependent manner.
Cell?Data
cell?lines:
Concentrations:Dissolved in DMSO, final concentrations ~100 μM
Incubation?Time:72 hours
Powder?Purity:≥99%
查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對(duì)應(yīng)頁(yè)面:https://www.aladdin-e.com/zh_cn/L408619.html
關(guān)鍵字: N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,di4-methylbenzenesulfonate
上海阿拉丁生化科技股份有限公司是A股上市公司((股票代碼:688179),專(zhuān)注于科研試劑的研發(fā)、生產(chǎn)和銷(xiāo)售,已陸續(xù)建立多個(gè)工廠(chǎng)和研發(fā)中心。作為領(lǐng)軍企業(yè),阿拉丁始終堅(jiān)持質(zhì)量第一,連續(xù)13年被評(píng)為“最受歡迎試劑品牌”。
阿拉丁目前常備庫(kù)存試劑產(chǎn)品品種超過(guò)7萬(wàn)種,SKU總數(shù)超過(guò)46萬(wàn),產(chǎn)品線(xiàn)涵蓋了化學(xué)試劑、生化試劑、藥靶配體、蛋白質(zhì)和抗體等多個(gè)領(lǐng)域,是國(guó)內(nèi)少數(shù)化學(xué)試劑到生物試劑全面發(fā)展的國(guó)產(chǎn)試劑品牌,產(chǎn)品同步發(fā)布在我們國(guó)內(nèi)外電商平臺(tái)。